GPCR HETEROMER INHIBITORS AND USES THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 1, 2022
app pub date -
May 14, 2020
filing date -
May 17, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to ADRB2 that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and ADRB2 agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for pharmaceutical compositions and kits comprising a CXCR4 inhibitor and an ADRB2 inhibitor, and methods for treating and using the same, and in the diagnosis and/or therapy for cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully